<DOC>
	<DOCNO>NCT00000737</DOCNO>
	<brief_summary>To obtain data safety administer megestrol acetate dronabinol single agent combination patient human immunodeficiency virus ( HIV ) -wasting syndrome . To obtain preliminary data efficacy single agent combination therapy megestrol acetate dronabinol regard weight gain , appetite increase quality life patient population . To obtain steady-state pharmacokinetics data megestrol acetate dronabinol administer single agent combination . HIV-wasting syndrome , characterize severely debilitate anorexia weight loss , particular concern exacerbate primary illness associate poor prognosis . Attempts maintain body mass use megestrol acetate dronabinol , two anti-cachectic drug , may prolong survival .</brief_summary>
	<brief_title>A Phase I/II Study Evaluate Single Agent Combination Therapy With Megestrol Acetate Dronabinol Treatment HIV-Wasting Syndrome</brief_title>
	<detailed_description>HIV-wasting syndrome , characterize severely debilitate anorexia weight loss , particular concern exacerbate primary illness associate poor prognosis . Attempts maintain body mass use megestrol acetate dronabinol , two anti-cachectic drug , may prolong survival . Fifty-six patient randomize one four treatment arm , follow : high-dose megestrol acetate alone ; dronabinol alone ; high-dose megestrol acetate combine dronabinol ; low-dose megestrol acetate combine dronabinol . Treatment continue 12 week . Patients evaluated toxicity , preliminary evidence response ( e.g. , weight gain ) , steady-state pharmacokinetics drug therapy .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Cachexia</mesh_term>
	<mesh_term>Wasting Syndrome</mesh_term>
	<mesh_term>HIV Wasting Syndrome</mesh_term>
	<mesh_term>Dronabinol</mesh_term>
	<mesh_term>Megestrol</mesh_term>
	<mesh_term>Megestrol Acetate</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Zidovudine ( AZT ) , didanosine ( ddI ) , dideoxycytidine ( ddC ) . If initiate new antiretroviral therapy , patient must stable dose least 4 week prior study entry . Maintenance suppressive therapy following , provide patient stable dose least 1 week prior study entry : Ganciclovir foscarnet CMV retinitis . Fluconazole , amphotericin B , flucytosine cryptococcosis . Amphotericin B disseminate histoplasmosis . Pyrimethamine , sulfadiazine , dapsone , clindamycin toxoplasmosis . Amikacin , clarithromycin , clofazimine , ethambutol , ciprofloxacin , rifampin disseminate Mycobacterium avium complex . Isoniazid , rifampin , ethambutol , pyrazinamide M. tuberculosis . Any follow provided patient stable dose least 1 week prior study entry : Trimethoprimsulfamethoxazole , aerosolize pentamidine , dapsone Pneumocystis carinii prophylaxis . Clotrimazole troche , nystatin suspension , ketoconazole , fluconazole oral candidiasis . Oral acyclovir mucocutaneous herpes simplex . Narcotic analgesic , tranquilizer , sedativehypnotics , anticholinergic agent provide patient stable dose least 1 week prior study entry . Patients must : HIV infection . HIVwasting syndrome anorexia . Life expectancy least 4 month . Ability tolerate oral therapy , feed , access much food desire dietary restriction . Prior Medication : Allowed : Prior zidovudine ( AZT ) , didanosine ( ddI ) , dideoxycytidine ( ddC ) . Prior maintenance suppressive therapy certain opportunistic infection , follow : Ganciclovir foscarnet CMV retinitis . Fluconazole , amphotericin B , flucytosine cryptococcosis . Amphotericin B disseminate histoplasmosis . Pyrimethamine , sulfadiazine , dapsone , clindamycin toxoplasmosis . Amikacin , clarithromycin , clofazimine , ethambutol , ciprofloxacin , rifampin disseminate Mycobacterium avium complex . Isoniazid , rifampin , ethambutol , pyrazinamide M. tuberculosis . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Major , acute opportunistic infection . Active neoplasms Kaposi 's sarcoma localize skin carcinoma . Diabetes , congestive heart failure , clinical ascites , uncontrolled hypertension . Persistent grade 3/4 diarrhea . Impaired oral intake , occur Candida esophagitis severe mouth ulcer . Clinically significant cardiac arrhythmia . Requirement anticonvulsant seizure disorder . Concurrent Medication : Excluded : Marijuana use . Anabolic steroid . Anticonvulsants seizure disorder . Alcohol barbiturate . Patients follow prior condition exclude : Diagnosis major , acute opportunistic infection within 2 month prior study entry . Hospitalization within 2 week prior study entry . History hypersensitivity reaction megestrol acetate , dronabinol , sesame oil ( component dronabinol capsule ) . History thromboembolic event . History psychiatric disorder depression . Prior Medication : Excluded : Prior dronabinol . Megestrol acetate within 2 month prior study entry . Marijuana within 1 month prior study entry . Anabolic steroid within 3 month prior study entry . Current drug alcohol abuse ( patient history occasional marijuana use eligible provide abstain use 1 month prior study entry agree refrain marijuana use study period ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 1994</verification_date>
	<keyword>Weight Loss</keyword>
	<keyword>Megestrol</keyword>
	<keyword>Cachexia</keyword>
	<keyword>Eating Disorders</keyword>
	<keyword>Tetrahydrocannabinol</keyword>
	<keyword>Appetite</keyword>
</DOC>